Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Novo Nordisk A/S — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.18, while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| FNGU | NVO | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $63.98 |
52-Week Low | $13.73 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $32.19, down 4.48% on the day, with recent volatility highlighted by a 16% single-session drop on June 5, 2026. Technical indicators show a bullish moving average signal but overbought RSI levels, with key support at $32 and resistance at $34. The product's inherent leverage amplifies both gains and losses, as seen in recent performance gaps versus the underlying index.
The outlook for FNGU is highly speculative, driven by leveraged exposure to mega-cap tech stocks. Investment opportunity lies in magnified upside during strong bull markets, but risks are severe, including decay from daily rebalancing and extreme volatility. Investors face potential rapid capital erosion in downturns, as evidenced by recent sharp declines.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
